theranos	LDT Validation Report	Theranos LDH Assay	Rev:
		CL-RPT-14068	1
Description	Validation Report for Modified Siemens Assay of Lactate Dehydrogenase (LDH) in Lithium Heparin Plasma		
Originator: Curtis Schneider		Date: 10/15/2013	

Validation of Modified Siemens Lactate Dehydrogenase (LDH) Assay

Author(s):

Signature: Patel	Date: 12/12/13
Name: Paul Patel, Ph.D.	Title: Team Lead, General Chemistry

Reviewer(s):

Signature:	Date:
Name:	Title:
Signature: DY	Date: 12/19/2013
Name: Daniel Young, Ph.D.	Title: Vice President

Approver(s):

Signature: A	Date: 12/12/2013
Name: Adam Rosendorff, M.D.	Title: Laboratory Director

9/24/15

Sunil S. Dhawan M.D.

Lactate Dehydrogenase (LDH) Plasma Assay

Overview

Lactate dehydrogenase (LD) activity is present in all cells of the body with highest concentrations in heart, liver, muscle, kidney, lung, and erythrocytes. Serum LD is elevated in a number of clinical conditions.

I. Method Principle

Lactate dehydrogenase catalyzes the conversion of L-lactate to pyruvate in the presence of nicotinamide adenine dinucleotide (NAD). The enzymatic activity of lactate dehydrogenase is proportional to the rate of production of NADH. The about of NADH produced in determined by measuring the increase in absorbance at 340/410 nm.

Reaction Equation

II. Definitions and Abbreviations

The following definitions and abbreviations are used in this document and related documents and attachments:

a. **Accuracy:** Accuracy is defined by CLSI as the closeness of agreement between a test result and an accepted reference value. Method accuracy is used in a different sense by the American Association of Pharmaceutical Scientists where it is expressed as percent relative error (%RE). Trueness, a related CLSI term, is the closeness of agreement between the average of a number of replicate measured quantity values and a reference quantity value.

b. **Analyte:** Component represented in the name of a measurable quantity. The closely related term measureand is defined as the particular quantity subject to measurement.

c. **Analytical sensitivity:** There are several alternative uses of this term. Most commonly, and for the purposes of this Validation Plan, it is used interchangeably with limit of detection. It is also used to describe the ability of an analytical method to assess small variations of the concentration of an analyte, such as the slope of the calibration curve (IUPAC).

d. **Analytical specificity:** Ability of a test or procedure to correctly identify or quantify an entity, including in the presence of interfering substance(s) or phenomena.

e. **Calibration:** Set of operations that establish, under specified conditions, the relationship between values of quantities indicated by a measuring instrument or measuring system, or values represented by a material measure or a reference material, and the corresponding values realized by standards. Under CLIA, calibration refers to the process of testing and adjusting an instrument, kit, or test system, to provide a known relationship between the measurement response and the value of the substance being measured by the test procedure (42 CFR 493.1217).

f. **Calibrator:** A substance, material, or article intended to be used to establish the measurement relationships of a diagnostic medical device.

g. **CLIA:** Clinical Laboratory Improvement Amendments of 1988. Congressional legislation that defined and requires specific quality assurance practices in clinical laboratories.

h. **CLSI:** Clinical and Laboratory Standards Institute.

i. **Coefficient of Variation:** The ratio of the standard deviation to the average, often multiplied by 100 and expressed as a percentage, abbreviated as %CV .

j. **Colorimetry:** A technique used to determine the concentration of colored compound(s) in solution.

k. **Interfering substance:** A substance or quantity thereof that is not the measurand but that affects the result of the measurement.

l. **IUPAC:** International Union of Pure and Applied Chemistry

m. **LDT:** Laboratory –developed Test.

n. **Linearity:** Linearity is the ability of a quantitative analytical method to provide results that are directly proportional to the concentrations of an analyte in test samples, within a given measuring interval. It is an important parameter to confirm when evaluating an analytical method because it verifies correct interpolation of results between points.

o. **LMR:** Lower end of the measuring range is the lowest level at which defined conditions, including all stated characteristic of the method, are met.

p. **LoB:** Limit of Blank is the highest value in a series of results on a sample that contains no analyte.

q. **LoD:** Limit of Detection is the lowest amount of analyte in a sample that can be detected with stated probability, although perhaps not quantified as an exact value.

r. **LoQ:** When used without a prefix, the Limit of Quantitation is the lowest actual concentration at which an analyte is reliably detected and at which uncertainty of the test result is less than or equal to the goal set by the manufacturer or laboratory. The term may also be used with prefixes L for lower (LLOQ) and U for upper (ULOQ), respectively. Note: LoB < LoD ≤ LoQ.

s. **Matrix:** All components of a material system, except the analyte. A specimen matrix is the biological milieu in which an analyte exists (e.g., plasma, serum, urine, or other body fluids).

t. **Measuring Interval (reportable range; analytical measurement range or AMR):** A measuring interval consists of all numeric values between the lower and upper numeric values for which a method can produce quantitative results suitable for clinical use. Where applicable, a linearity study is frequently used to establish or verify the measuring interval that can be reported for a measurement method. Alternatively, the lower limit of the measuring interval may be assigned as the LoQ (LLOQ).

u. **Precision:** Precision is the closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions. It is usually expressed numerically in terms of standard deviation (SD) or percent Coefficient of Variation (%CV).

v. **Reference interval:** The interval between and including two reference limits. It is common practice to define a reference limit so a stated fraction of the reference values is less than or equal, or greater than or equal, to the respective upper or lower limit.

w. **SOP:** Standard Operating Procedure.

x. **Spectrophotometry:** The quantitative measurement of the transmission (or reflection) properties of a material as a function of wavelength.

y. **Testing System:** The entirety of the testing process, including instrument, sample, reagents, supplies, and procedures. Personnel are sometimes included in the definition.

III. Pre-clinical Validation

a. Analytical Measurement Range

i. Limits of Blank, Detection and Quantitation

The limits of blank, detection, and quantitation were determined to be 0.0 U/L, 2.6 U/L and 2.6 U/L respectively.

Limit of blank

CLSI guideline EP17-A section 4.3.1

Level	Number of samples	N	Mean	SD
Blank	1	20	0.0	0.0
Alpha	5%			
Parametric LoB	0.0			

Limit of detection

CLSI guideline EP17-A section 4.3.2

Level	Number of samples	N	Pooled SD
Low	1	20	1.6
Beta	5%		
Parametric LoD	2.6		

Limit of quantitation

CLSI guideline EP17-A section 5.1

Level	Number of samples	N
Low	1	20
Bias	-4.3	
Pooled Imprecision	1.6	
95% total error	-7.3	
Allowable error	8	
LoQ	2.6	

95% total error is less than allowable error: 20%.

LoQ has been established.

ii. Linearity

The Analytical Measurement Range (AMR) including linear measurement interval has been determined for Lactate Dehydrogenase in plasma. This method is linear from 22.4 – 730.0 U/L within the 10% allowable non-linearity in this interval.



Level	Mean	Linear fit	Nonlinear fit (3rd order polynomial)	Nonlinearity	Allowable nonlinearity
1	22.4	17.6	19.6	2.2	4.4
2	202.8	207.3	214.1	6.9	39.6
3	386.6	379.8	369.9	-9.9	72.0
4	557.4	583.5	570.1	-13.4	110.0
5	730.0	711.0	725.2	14.2	133.8

Nonlinearity is less than allowable nonlinearity: 20%.
Performance requirement verified over the measuring interval.

b. Analytical Specificity

The analytical specificity for this assay was determined by testing the effect of hemoglobin (100 mg/dL), bilirubin (10 mg/dL) and triglycerides (400 mg/dL) on plasma samples spiked with the interferents and then compared with un-spiked controls. Lactate Dehydrogenase concentration at which the interference testing was performed at was 267 U/L. Non-interference was defined as the mean result from testing of spiked samples within 10% of the mean of the un-spiked samples. Recoveries were within 95.5% to 99.6% (see table below).

Table 1. Interference Testing For Lactate Dehydrogenase

Analyte (U/L)	% Recovery		
	Interferent		
	Bilirubin (10 mg/dL)	Hemoglobin (100 mg/dL)	Triglycerides (400 mg/dL)
Lactate Dehydrogenase (267)	97.1	N/A*	97.8

* N/A Not Applicable

No significant interference was observed.

c. Precision

Level = Level 1

Number of observations	80
Number of runs	40
Number of days	20
Runs per day	2
Replicates per run	2
Mean	111.4

	SD	95% CI	CV	Allowable Total SD
Repeatability	2.3	1.9 to 2.9	2.1%	-
Between-run	1.2		1.1%	-
Between-day	0.6		0.6%	-
Within-laboratory	2.7	2.3 to 3.2	2.4%	22.3

Imprecision is less than allowable total imprecision: 20% upto 400U/L then 10%.

Level = Level 2

Number of observations	80
Number of runs	40
Number of days	20
Runs per day	2
Replicates per run	2
Mean	159.2

	SD	95% CI	CV	Allowable Total SD
Repeatability	3.8	3.1 to 4.9	2.4%	-
Between-run	0.8		0.5%	-
Between-day	2.9		1.8%	-
Within-laboratory	4.8	4.1 to 5.9	3.0%	31.8

Imprecision is less than allowable total imprecision: 20% upto 400U/L then 10%.

Level = Level 3

Number of observations	80
Number of runs	40
Number of days	20
Runs per day	2
Replicates per run	2
Mean	395.3

	SD	95% CI	CV	Allowable Total SD
Repeatability	7.1	5.8 to 9.1	1.8%	-
Between-run	0.0		0.0%	-
Between-day	13.0		3.3%	-
Within-laboratory	14.8	11.7 to 20.2	3.7%	79.1

Imprecision is less than allowable total imprecision: 20% upto 400U/L then 10%.

The percent CV reported as zeros in the above precision summary are most likely a consequence of rounding the values in StatisPro.

IV. *Clinical Validation*

a. Method Comparison with Predicate (Accuracy/Comparability)

To test the accuracy of the assay on the Theranos System, Forty (48) unique patient samples were screened on the predicate method (Siemens, Advia) and on the Theranos method. One sample was excluded as an outlier (mean absolute difference greater than 4). Using the predicate method twenty (20) values were within the reference range (120 - 246 U/L), one value (1) was below the reference range, and twenty six (26) were above the reference range. Based on the results of the data examination, either a simple linear regression or alternative procedures were used to

estimate expected (average) bias and the confidence interval of expected bias at the desired medical decision level(s) as per CLSI guidance EP09-A2. StatisPro was used for bias calculations. These estimates were compared with internal criteria to judge the acceptability of the Theranos method. Each sample was run in duplicate on the predicate, and the average used for comparison to the Theranos method. Some samples were stored before analysis on both methods. If the confidence interval for the predicted bias includes the defined acceptable bias or if the acceptable bias is greater than the higher limit of the confidence interval of the predicted bias, then the data do not show that the bias of the Theranos method is different from the acceptable bias or there is a high probability (97%) that the predicated bias is acceptable, respectively. The acceptable bias at each medical decision level was determined based on the total allowable error (TEa) minus the measured precision at the level closest to that decision level. Total allowable error (TEa) was taken from American Proficiency Institute (API) peer proficiency testing criteria or CLIA proficiency testing criteria for acceptable analytical performance, as printed in the Federal Register February 28, 1992;57(40):7002-186, when available. The TEa for LDH is 20%. The table below shows the allowable bias and precision at 2 levels (values shown in parentheses) and the corresponding closest medical decision limits.

Table 2. Allowable Bias and Precision at the Medical Decision Levels

Medical Decision Levels (U/L)	**150 (159.2)**	**500 (395.3)**
Precision (%)	**1.8**	**3.3**
Allowable Bias (%)	**18.2**	**16.7**



1. Detected outliers greater than 4* mean absolute difference and 4 * mean relative absolute difference

Figure 1. Graph showing Theranos method versus Predicate Method (Siemens Advia).

Simple linear regression was used to establish a slope, intercept and an r^2. The slope, intercept and clinical correlation were determined to be 1.12, -35.24 and 0.99 respectively.

Comparability

CLSI guideline EP09-A2-IR section 7

Level ID	Value	Difference	SE	95% CI	Allowable difference
	150.000000	-16.6600278	2.46152227	21.6177881 to -11.7022	24.0000000
	300.000000	1.9192123	1.79109965	-1.6882476 to 5.5266722	48.0000000
	500.000000	26.6915325	1.97744231	22.7087592 to 30.674305	80.0000000

Difference is less than allowable bias: 16.2% upto 150U/L then 16%.

The difference between the two methods is not greater than the allowable difference. The performance requirement is verified.

b. Transference and Verification of Reference Interval (Venous)

Reference ranges were modified by applying the regression equation to the lower and upper reference limits of existing reference interval to generate a new reference range. New reference ranges were verified using a minimum of twenty (20) new normal subjects

New reference ranges were verified using a total of forty nine (49) new normal subjects with matched Lithium heparin venous and finger sticks samples. For a reference range to pass verification, 95% of values should fall within the upper and lower reference limits and 5% or fewer values fall outside of the upper and lower reference limits. For venous verification 48 (98%) values fell within the new reference range and 1 (2%) values fell outside the new reference range. See graphs below for venous samples verification.



Figure 2. Graph showing venous sample reference range verification.

c. Verification of Reference Interval with Finger Stick Samples

New reference ranges were also verified with venous matched finger sticks (Lithium heparin) samples from a total of Twenty three (23) new normal subjects. The finger stick samples were collected in a Theranos blood collection device (BCD) configured with two separate Lithium heparin vessels. For finger stick verification 22 values (95.6 %) fell within the new reference range and 1 value (4.4%) fell outside the new reference range. See graphs below for finger stick samples verification.



Figure 3. Graph showing Finger stick sample reference range verification.

The new reference range for finger stick lactate dehydrogenase was determined to be 99 - 240 U/L.

VI. Stability

a. Reagents

On-board Reagent Stability

System	Stability
ADVIA 1200	30 days
ADVIA 1650/1800	30 days
ADVIA 2400	30 days

For all systems, unopened reagents are stable until the expiration date printed on the product label when stored at 2°C - 8°C. Do not freeze the reagents.

For additional details, refer to the Methods Introduction section of the system-specific Operator's Guide.

b. Sample

Plasma samples for lactate dehydrogenase analysis are stable for 1 week at 2-8 °C, or at least 2 week at -20 °C.

c. Calibrators

Calibration uses a fixed system Factor Value (FV), which is based on the established molar extinction coefficient of NADH at 340 nm, adjusted by the patient sample correlation to the IFCC reference method. One unit is the amount of enzyme required to produce 1 µmol of NAD per minute under the conditions of the method.